External Validation of the New 2023 International Federation of Gynecology and Obstetrics Staging System in Endometrial Cancer Patients: 12-Year Experience from an European Society of Gynecological Oncology-Accredited Center
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The new FIGO staging system for endometrial cancer better categorizes early-stage disease. While it causes stage shifts, its prognostic precision is comparable to the previous system.
Area Of Science
- Gynecologic Oncology
- Molecular Pathology
- Clinical Staging Systems
Background
- Endometrial cancer management is evolving with new molecular classifications.
- The FIGO (International Federation of Gynecology and Obstetrics) recently updated its staging system for endometrial cancer, incorporating molecular features and refining early-stage classifications.
Purpose Of The Study
- To compare the 2009 and 2023 FIGO staging systems for endometrial cancer.
- To evaluate the prognostic accuracy of the new FIGO staging system.
Main Methods
- Retrospective analysis of endometrial cancer patient records from 2012-2023.
- Collection of patient characteristics, oncological outcomes, and follow-up data.
- Assessment of stage shifts and survival data (Progression-Free Survival - PFS).
Main Results
- A stage shift occurred in 15.5% of patients, primarily from early stages (2009 IA/IB) to 2023 stage IIC.
- Stage II disease showed improved median and 5-year PFS.
- No significant difference in prognostic precision was found between the two FIGO staging systems.
Conclusions
- The 2023 FIGO staging system offers improved differentiation of early-stage endometrial cancer into prognostic groups.
- The new staging system demonstrates comparable prognostic precision to the 2009 system.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.